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S U M M A R Y
Introduction: Human Papilloma Virus (HPV) is small DNA virus mostly infecting mucosa and cutaneous
keratinocytes. So far, more than 200 Human papillomaviruses are known. HPV have been divided into
high- and low-risk on the basis of their oncogenic potential. High risk HPV is considered to be the main
etiological cause for cervical cancer.
Objective: The current study was designed to screen the local cervical cancer patients from the twin
cities of Pakistan for the occurance of high risk HPV.
Methodology: A total of 67 formalin ﬁxed parafﬁn-embedded samples of cervical cancer biopsies were
obtained from the government hospitals in Islamabad and Rawalpindi. Cervical cancer biopsies were
examined for the presence of HPV DNA. Polymerase chain reaction (PCR) was used for the ampliﬁcation
of a region in the HPV-L1 gene for the general detection of the Papilloma virus and for the genotype
speciﬁc detection of high risk HPV 16 and 18 using the GP5/GP6 primers and genotype speciﬁc primers,
respectively.
Results: HPV DNA was detected in 59 out of 67 samples analyzed. 30 samples showed the presence of
HPV16 while 22 samples were positive for HPV18. HPV subtype could not be determined in 7 samples.
Conclusion: Our results show a strong association between HPV infection and cervical cancer among
women in twin cities of Pakistan. One way to minimize the disease burden in relation to HPV infection in
Pakistani population is the use of prophylactic vaccines and routine screening. An early diagnosis of HPV
infection will allow better health management to reduce the risk of developing cervical cancer.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Human Papilloma Virus (HPV) belongs to a large and diverse
Papillomaviridae family of small, non enveloped DNA viruses.1
Several hundred species of Papilloma viruses, infecting a wide
range of hosts ranging from mammals to birds and reptiles, have
been identiﬁed so far. Infection of papilloma viruses in these
species is either asymptomatic or causes warts or papillomas. The
association between HPV infection and the development of
cervical, anal, and genital lesions (abnormality in the tissue) and
the cancers has been conﬁrmed since 1976.2,3 HPV is the most
common sexually transmitted virus in both men and women.4Over
200 different subtypes of HPV are known, and are differentiated on
the basis of their genetic sequences.5 The majority of the types are* Corresponding author. Tel.: +92-51-9085-6139.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).epitheliotropic infecting mucosa and cutaneous keratinocytes.
Mucosal infecting HPV are further subdivided into low or high risk
on the basis of their oncogenic potential. Low-risk HPV types lead
to the development of benign neoplasms, such as warts and
condyloma acuminatum, whereas high-risk HPV types infect the
anogenital tract and lead to malignant neoplasms, such as cervical
cancer.6,7 High-risk HPV strains such as HPV 16 and 18 causes
about 70% of cervical cancers, while other high risk HPV genotypes
show an association with more than 20% of cervical cancers
globally.8–10 Low-risk HPV 6 and 11 cause about 90% of genital
warts and benign neoplasm, which rarely develop into cancer.6,7
According to the International Agency for Research on Cancer
(IARC-WHO), Cervical cancer is the fourth most common cancer in
women, with an estimated 528,000 new cases and 266,000 deaths
worldwide during 2012.11 The use of prophylactic vaccine and
routine cervical testing through Papanicolaou testing (also
commonly known as Pap smear testing) has resulted in a decrease
in cervical cancer incidence by over 70 percent.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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related death for women in the developing countries.11,12 In Asia,
cervical cancer is more widespread, where it records around half of
the world’s new cases of cervical cancer each year. This situation
could be related to the lack of access to the proper medical services
and expensive vaccinations. Unfortunately not all cancer cases are
registered, and that is why cancer is underestimated by 40 to
50 percent.13
Pakistan is a developing country, and HPV screening in Pakistan
is normally not practiced. There is a lack of documented studies in
relation to the HPV associated cervical cancer in local patients. For
a very long time, there were no data regarding HPV prevalence in
Pakistan. Recently, however, small regional studies indicating HPV
prevalence have started to emerge, but they are not the true
representation of the actual cervical cancer related disease burden.
This is mainly because of the lack of an HPV program as a part of
regular screening.14–16
According to Information center on HPV and cancer (ICO),
cervical cancer in Pakistan ranks as the 3rd most frequent cancer
among women, and every year 5233 women in Pakistan are
diagnosed with cervical cancer, while 2876 die of the disease.17
Acquiring the data of HPV associated cervical cancer is essential in
order to lower the burden of cervical cancer and to check the
potential relevance of HPV vaccination. Therefore the aim of this
study was to screen the local cervical cancer patients from twin
cities of Pakistan for the prevalence of high risk HPV, i.e. subtypes
16 and 18.
2. Materials and methods
2.1. Sample collection
Current study was planned and conducted at Atta-ur-Rahman
School of Applied Biosciences (ASAB) National University of
science and technology Islamabad (NUST) Pakistan. The study
was approved by Ethics Committee of NUST. A total of 67 formalin
ﬁxed parafﬁn-embedded cervical cancer biopsy samples reported
from 2010 to 2013 were obtained from the government hospitals
of Twin cities (Islamabad and Rawalpindi) including Pakistan
Institute of Medical Sciences (PIMS), Holy Family and Railway
General Hospital Rawalpindi. Informed consent was obtained from
patients included in the study. PIMS hospital is one of the biggest
hospital of the federal capital. The patients visiting the PIMS
hospital are from various parts of the country, especially from
Punjab and Khyber Pakhtun Khwa (KPK) province and symbolize
various ethnicities and broad social backgrounds. Biopsy samples
were histopathologically conﬁrmed by histopathologists as
squamous cell carcinoma, adenocarcinoma, cervical intraepithelial
neoplasia I (CINI), cervical intraepithelial neoplasia II (CINII) or
cervical intraepithelial neoplasia III (CINIII).Table 1
Oligonucleotide sequences used as primers for HPV Genotyping
Primers Primer sequence (50-) Targe
Beta globin FP- ACACAACTGTGTTCACTAGC b-glo
RP- CAACTTCATCCACGTTCACC
GP 5/ GP6 FP- TTTGTTACTGTGGTAGATAC L1 
RP- GAAAAATAAACTGTAAATCA
TS16 FP- GGTCGGTGGACCGGTCGATG L1 
RP- GCAATGTAGGTGTATCTCCA
TS18 FP- CCTTGGACGTAAATTTTTGG L1 
RP- CACGCACACGCTTGGCAGGT
Beta globin for b-globin gene, GP5/GP6, general primers for HPV; TS16-F/TS16-R for HP
primer, RP; reverse primer.2.2. HPV detection through PCR
DNA was extracted from parafﬁn embedded tissue samples.
Parafﬁn embedded cervical cancer tissue biopsy sections 10-
15 mm thick were deparafﬁnized with xylene. Rehydration in
graded ethanol was carried out as described by Wright and
Manos.18 The extracted DNA was subjected to PCR.
The consensus sequence of HPV L1 gene was ampliﬁed by using
previously reported sets of primers GP5+/GP6+ that can detect up
to 44 different HPV genotypes (Table 1).19 The PCR conditions for
these primers were as follows; for primers GP5/GP6, the total
25 ml PCR reaction mixture contained 100 ng -200 ng of template
DNA, 10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1% Triton X-100, 1 mM
MgCl2, 200 mM deoxynucleotide triphosphates (dNTPs), 0.2 pmol
of each primer, and 0.2 U of Taq polymerase. The PCR thermal
proﬁle was: 95 8C for 5 min, and 35 cycles of 94 8C for 30 s, 45 8C for
30 s, 72 8C for 30 s, and ﬁnal extension of 5 min at 72 o C. PCR
conditions for TS-16 and TS-18 primers were the same as for the GP
primers, except that for TS-16 and TS-18 the annealing tempera-
tures were 58 8C and 56 8C respectively. For beta globin primers,
the PCR thermal proﬁle was 94 8C for 5 min, and 35 cycles of 94 8C
for 30 s, 55 8C for 30 s, 72 8C for 30 s, and 5 min ﬁnal extension at
72 8C.
3. Results
Cervical cancer biopsies from 67 patients were collected and
were pathologically conﬁrmed for cervical cancer by histopathol-
ogists. DNA was isolated from tissue samples. As an internal
control for checking the quality of extracted DNA, b-globin gene
was ampliﬁed through PCR. All the samples were ﬁrst subjected to
HPV DNA detection using consensus primers based on conserved
region of L1 gene. The parafﬁn embedded biopsies were further
screened for high risk HPV type 16 and 18 with the help of PCR.
HPV type 16 was detected in 44.8% (30) of cervical cancer biopsies,
while 32.8% (22) of cervical specimens were positive for HPV 18.
10.4% (7) of cervical specimens were positive for HPV but negative
for type 16 or 18, whereas 11.9% (8) of cervical cancer biopsies
were found to be HPV negative (Figure 1).
Figure 2 represents the 2% Agrose gel showing ampliﬁed 150 bp
region of L1 gene of HPV. Out of 67 formalin-ﬁxed parafﬁn-
embedded cervical cancer samples 59 were found to be HPV
positive.
The 2% agarose gels for HPV type 16 and HPV type 18 are shown
in Figure 3 and 4, respectively. The PCR product of 96 bp represents
HPV type 16 (Figure 3) and 115 bp represents type 18 (Figure 4).
The incidence of the HPV according to histopathological
diagnosis (Table 2) revealed the prevalence of HPV 16 (42%) and
18% (45%) at comparable levels in squamous cell carcinoma of the
cervix, while in adenocarcinoma HPV16 (50%) was more prevalent
as compared to HPV 18 (38.8%). HPV16 was frequently found (87%)t gene Product size Annealing temperature
bin gene 110 bp 558 C
150 bp 458 C
96 bp 588 C
115 bp 568 C
V subtype 16 and TS18-F/TS-18R for HPV subtype 18. TS; type speciﬁc, FP; forward
Figure 1. Distribution of HPV types 16 and 18 in cervical lesions. 59 out of 67 formalin-ﬁxed parafﬁn-embedded cervical cancer samples were HPV positive. HPV type 16 was
detected in 44.8% (30) of cervical cancer biopsies, and 32.8% (22) of cervical specimens were positive for HPV 18. 10.4% (7) samples were HPV positive but the HPV type could
not be determined, whereas 11.9% (8) cervical cancer biopsies were found to be HPV negative.
Figure 2. PCR-based detection of HPV-DNA in cervical lesions. 2% Agarose gel showing 150bp long PCR product obtained by ampliﬁcation of a region in L1 gene in HPV DNA by
using GP5+/GP6+ consensus primers. Lane M shows 50 bp ladder. Sample numbers 1-5 are positive for HPV; lanes 6 and 7 show positive and negative control respectively.
Figure 3. PCR-based detection of HPV-16 in cervical lesions. 2% Agarose gel showing 96 bp long PCR product obtained by ampliﬁcation of a region in L1 gene in HPV-16 by
using type-speciﬁc primer pair (TS16). Lane M shows 50 bp ladder. Sample numbers 1-2 are positive for HPV16, Lane 3 shows negative control.
Figure 4. PCR-based detection of HPV-18 in cervical lesions. 2% Agarose gel showing 115bp long PCR product obtained by ampliﬁcation of a region in L1 gene in HPV-18 by
using type-speciﬁc primer pair (TS18). Lane M shows 50 bp ladder. Sample numbers 1-4 are positive for HPV18 with 115 bp, Lanes 5 & 6 show negative and positive control.
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Table 2
HPV genotype distribution in women with cervical abnormalities
HistoPathological
Status
HPV genotypes Total HPV
positive
16 18 untyped HPV
SCC 14 (42.42%) 15 (45.45%) 4 (12.12%) 33
Adenocarcinomas 9 (50%) 7 (38.88%) 2 (11.11%) 18
CIN1 - - 1 (100%) 1
CIN2 1(100%) - - 1
CIN3 6 (100%) - - 6
Total 30 22 7 59
SCC; Squamous cell carcinoma, CIN; Cervical intraepithelial neoplasia.
Table 3
Distribution of HPV genotype in different age groups
Age Group HPV genotype Total HPV
positive
16 18 untyped HPV
21-30 1(50%) - 1(50%) 2
31-40 4 (57.14%) 2 (28.57%) 1(14.28%) 7
41-50 7 (50%) 5 (35.71%) 2 (14.28%) 14
51-60 12 (63.15%) 7 (36.84%) - 19
61-70 2 (25%) 3 (37.5%) 3 (37.5%) 8
71-80 1(100%) - - 1
Unknown 3 (37.5%) 5 (62.5%) - 8
Total 30 22 7 59
S. Gul et al. / International Journal of Infectious Diseases 34 (2015) 14–19 17in cervical intraepithelial neoplasia samples CINII CINIII. None of
the pre-malignant samples were positive for HPV-18 (Figure 5).
The distribution of HPV in different age groups is shown in
Table 3 and Figure 6. The HPV induced cervical cancer rate is higher
in the age group of 41-60 years. HPV 16 was found to be
comparatively more prevalent than HPV 18 among the women
aged between 21 and 60, while HPV 18 was found in patients older
than 60.
4. Discussion
Cervical cancer is the fourth most common malignancy among
women worldwide.20 A wide range of regional diversity in the
incidence of cervical cancer in different parts of the world is
evident from several reports. Population-based cancer registries
are a goldmine for calculating the cancer burden in a deﬁned
population. Unfortunately, these programs are either non-existent
or are partially functional in most developing countries, thus
preventing the estimation of actual disease burden.20 In the case of
cervical cancer, the situation of inadequate health care facilities,
lack of cancer registries, gynecological screening and HPV testing,
is further compounded by additional factors such as socio-
economic issues, beliefs and culture that may prevent estimation
of the actual disease burden.21 The conservative societies, morals,
laws, and beliefs used by societies may protect against the spread
of sexually transmitted disease but can equally make such issues
taboo, resulting in under reporting. Hence there is no or very little
data available to calculate the HPV-associated disease burden in
Pakistani women.16 The cervical cancer incidence, althoughFigure 5. HPV genotype distribution among women according to histopathological dia
The rate of SCC was higher and associated with HPV18, the incidence of CINI, CINII we
associated with incidence of HPV16.difﬁcult to assess precisely, is estimated to be low in Pakistan as
compared to the rest of the world.20 The current data available on
cervical cancer incidence and its association with HPV is the result
of opportunistic cervical cancer screening in some parts of the
country. Although, studies showing association of HPV in cervical
cancer have started to emerge, there seems to be regional disparity
regarding HPV genotype prevalence and its etiological role in
cervical cancer in different parts of Pakistan, highlighting the
essential need for further investigation.22–24
High-risk HPV infection accounts for more than 99% of cervical
cancer cases and approximately 5 percent of all cancers
worldwide.25 As a necessary factor for the development of cervical
malignancies, high risk HPV is often found in the pre-malignant
genital lesions.3,9 In order to establish HPV in the etiology of the
local cervical cancers, the PCR-based method was used to detect
HPV in pre-malignant and malignant lesions. HPV DNA was
detected in 88% of all the cervical cancer samples and in all cervical
intra-epithelial lesions (CINI-III). Genotype speciﬁc primers were
used for the detection of high risk HPV subtypes HPV 16 (TS 16) and
HPV18 (TS 18). HPV 16 was detected in 14/33, 9/18 and 7/8 of
Squamous cell carcinoma (SCC), Adenocarcinoma and CIN cervical
lesions respectively. HPV 18 was detected in 15/33, 7/18 of SCC,
Adenocarcinoma samples. According to the International Associa-
tion for Research in Cancer (IARC), the most prevalent high risk
HPV genotypes found to be associated with cervical cancer are:
HPV16 (53%), HPV18 (15%), HPV45 (9%), HPV31 (6%), and HPV33
(3%). HPV 16 was found to be universally common but HPV 18 was
particularly common in South East Asian countries.26 Likewise, ourgnosis.
re low, and the incidence of Adenocarcinoma and CINIII was moderate and were
Figure 6. Distribution of HPV genotype in different age groups. The maximum rate of cervical cancer was found in age group 51-60, followed by the 41-50 and 31-40 age
groups respectively. The rates of HPV16 & HPV18 were higher in age group 51-60.
S. Gul et al. / International Journal of Infectious Diseases 34 (2015) 14–1918data reports a higher prevalence of HPV 18 in comparison to that
reported in other parts of the world. The current study shows the
occurrence of HPV 16 and 18 in cervical lesions at a comparable
rate. HPV 16 and 18 was detected in 42% and 45% of SCC and in 50%
and 38.8% of Adenocarcinoma sections respectively. The seven
HPV+ cervical cancer sections that were negative for HPV16 and
18 are predicted to harbour other high risk HPV subtypes. HPV DNA
was not detectable in eight cervical cancer samples through the
GP5/GP6 primer pair. Other studies carried out locally, likewise
report a minor subpopulation with undetermined genotype
(HPV16-/HPV18). Studies reporting the prevalence of high risk
HPV subtypes other than HPV 16 and 18 are scarce in Pakistan.
However, a study carried out in Karachi reported the presence of
HPV45, HPV56, 59 and 33 in a minor subpopulation of Invasive
cervical carcinoma (4.4%, 2.2%, 1.1% and 1.1%) evident of oncogenic
HPV subtypes other than HPV 16 and 18.23 Major high risk HPV
subtypes reported in neighbouring countries such as Saudi Arabia
include: HPV 11, 33, 31, 39, 45, 51, 52, 53, 58, 59, 66, 68 and 73.28
HPV subtypes reported in Iran include; HPV 6, 11, 31, 33, 35,39, 42,
43, 44, 45,51, 52, 56, 58, 59, 66 and 68.29 Most of these studies,
however, are based on normal or abnormal cervical cytology
screening results obtained from women visiting the gynecologic
institutes.28,29 As most HPV infections are self resolving, these
subtypes do not represent the major oncogenic subtypes, as
evident from the prevalence of HPV16 and 18 in most of the
cervical cancer samples from Pakistan and its neighboring
countries, including Iran and Saudi Arabia.30–38 Although most
of the studies are in agreement, regional differences within
Pakistan are evident. A study carried out in Karachi reported HPV
prevalence in 18% of cervical cancer samples.27 This highlights the
need for a systematic and large scale study based on multiple
detection techniques. Most of the studies are based on HPV
detection through GP5/GP6 primers which can detect forty four
subtypes of HPV. It might be possible that HPV variants in Karachi
are not detectable through this primer pair, which calls for a more
detailed analysis of the local cervical cancer samples. Current data
based on cervical cancer patients from the twin cities of Pakistan,
however, show the effective use of GP5/GP6 primer pairs for the
detection of HPV DNA in majority of samples (88%). A more
detailed analysis is required for the 12% of cervical cancer samples
found to be negative for HPV DNA through GP5/GP6 primers.Intratypic sequence variation has been found in HPV early genes;
E2, E4, E5, E6, and E7. These variations are reported to have
functional signiﬁcance, correlating with pathogenicity and onco-
genicity of speciﬁc HPV variants.39 Intratypic sequence variation
appears to vary geographically and also with the ethnic origin of
the population. There are an inadequate number of reports
regarding HPV 16 and 18 variants from this region of the world.
Therefore, sequence analysis of HPV 16 and 18 positive samples is
required to gain insight about the locally prevalent variants and for
designing therapeutic strategies and disease management.40
Age plays an important role in cervical cancer. More than 50% of
cervical cancer cases were in women aged between 41-60 years of
age. A study carried out in 2010 reported overall low prevalence of
HPV infection in the general population with no evidence of higher
HPV prevalence in young women. HPV positivity was associated
with factors such as women married to either an older man with
history of partners, or who were in multiple relations.23 Therefore,
the use of prophylactic vaccine by the susceptible population can
reduce the disease burden. High costs of vaccine and lack of
knowledge about the disease and its prevention are the biggest
hurdles in its effective use. There is an urgent need for programs to
educate people, even the health care staff.41 Based on these results,
it can be concluded that there is a growing need for routine
gynecological screening, HPV testing, and awareness programs in
order to determine the HPV-related disease burden and its
management. Dissemination of knowledge pertaining to the
HPV related diseases, risk factors, and its prevention to all women
is necessary to reduce the disease burden in future.41,42
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